AAAAAA
Results: 26-49/49
Authors:
Dalton, LW
Pinder, SE
Elston, CE
Ellis, IO
Page, DL
Dupont, WD
Blamey, RW
Citation: Lw. Dalton et al., Histologic grading of breast cancer: Linkage of patient outcome with levelof pathologist agreement, MOD PATHOL, 13(7), 2000, pp. 730-735
Authors:
Simpson, JF
Gray, R
Dressler, LG
Cobau, CD
Falkson, CI
Gilchrist, KW
Pandya, KJ
Page, DL
Robert, NJ
Citation: Jf. Simpson et al., Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group companion study, EST 4189, J CL ONCOL, 18(10), 2000, pp. 2059-2069
Authors:
Gobbi, H
Arteaga, CL
Jensen, RA
Simpson, JF
Dupont, WD
Olson, SJ
Schuyler, PA
Plummer, WD
Page, DL
Citation: H. Gobbi et al., Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas, HISTOPATHOL, 36(2), 2000, pp. 168-177
Authors:
Friedenreich, CM
Bryant, HE
Alexander, F
Hugh, J
Danyluk, J
Page, DL
Citation: Cm. Friedenreich et al., Risk factors for benign proliferative breast disease, INT J EPID, 29(4), 2000, pp. 637-644
Authors:
Hammond, MEH
Fitzgibbons, PL
Compton, CC
Grignon, DJ
Page, DL
Fielding, LP
Bostwick, D
Pajak, T
Citation: Meh. Hammond et al., College of American Pathologists Conference XXXV: Solid tumor prognostic factors - Which, how and so what? Summary document and recommendations for implementation, ARCH PATH L, 124(7), 2000, pp. 958-965
Authors:
Fitzgibbons, PL
Page, DL
Weaver, D
Thor, AD
Allred, C
Clark, GM
Ruby, SC
O'Malley, F
Sinpson, LF
Connolly, JL
Hayes, DF
Edge, SB
Lichter, A
Schnitt, SJ
Citation: Pl. Fitzgibbons et al., Prognostic factors in breast cancer - College of American Pathologists Consensus Statement 1999, ARCH PATH L, 124(7), 2000, pp. 966-978
Authors:
Fitzgibbons, PL
Connolly, JL
Page, DL
Citation: Pl. Fitzgibbons et al., Updated protocol for the examination of specimens from patients with carcinomas of the breast - A basis for checklists (Reprinted from Arch Pathol Med, vol 121, pg 27, 1997), ARCH PATH L, 124(7), 2000, pp. 1026-1033
Authors:
Page, DL
Ruby, SG
Citation: Dl. Page et Sg. Ruby, Protocol for the examination of specimens from patients with malignant adrenal cortical tumors and pheochromocytomas, exclusive of neuroblastoma and other adrenal medullary tumors of childhood - A basis for checklists, ARCH PATH L, 124(1), 2000, pp. 17-20
Authors:
Simpson, JF
Page, DL
Citation: Jf. Simpson et Dl. Page, The p53 tumor suppressor gene in ductal carcinoma in situ of the breast, AM J PATH, 156(1), 2000, pp. 5-6
Authors:
Gobbi, H
Dupont, WD
Simpson, JF
Plummer, WD
Schuyler, PA
Olson, SJ
Arteaga, CL
Page, DL
Citation: H. Gobbi et al., Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia, J NAT CANC, 91(24), 1999, pp. 2096-2101
Authors:
Lack, EE
Askin, FB
Dehner, P
Page, DL
Weiss, LM
Citation: Ee. Lack et al., Recommendations for reporting of tumors of the adrenal cortex and medulla, AM J CLIN P, 112(4), 1999, pp. 451-455
Authors:
Norgaard, P
Law, B
Joseph, H
Page, DL
Shyr, Y
Mays, D
Pietenpol, JA
Kohl, NE
Oliff, A
Coffey, RJ
Poulsen, HS
Moses, HL
Citation: P. Norgaard et al., Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis, CLIN CANC R, 5(1), 1999, pp. 35-42
Authors:
Gobbi, H
Atkinson, JB
Kardos, TF
Simpson, JF
Page, DL
Citation: H. Gobbi et al., Inflammatory myofibroblastic tumour of the breast: report of a case with giant vacuolated cells, BREAST, 8(3), 1999, pp. 135-138
Natural history of ductal carcinoma in situ should be viewed from a publichealth perspective - Reply
Authors:
Page, DL
Dixon, JM
Citation: Dl. Page et Jm. Dixon, Natural history of ductal carcinoma in situ should be viewed from a publichealth perspective - Reply, BREAST, 8(3), 1999, pp. 155-155
Authors:
Lack, EE
Askin, FB
Dehner, LP
Page, DL
Weiss, LM
Citation: Ee. Lack et al., Recommendations for reporting of tumors of the adrenal cortex and medulla, HUMAN PATH, 30(8), 1999, pp. 887-890
Authors:
Gobbi, H
Simpson, JF
Jensen, RA
Coogan, AC
Page, DL
Citation: H. Gobbi et al., Prostatic adenocarcinoma with glomeruloid features, HUMAN PATH, 30(1), 1999, pp. 111-112
Authors:
Page, DL
Simpson, JF
Citation: Dl. Page et Jf. Simpson, Ductal carcinoma in situ - The focus for prevention, screening, and breastconservation in breast cancer, N ENG J MED, 340(19), 1999, pp. 1499-1500
Authors:
Page, DL
Anderson, TJ
Carter, BA
Citation: Dl. Page et al., Minimal solid tumor involvement of regional and distant sites - When is a metastasis not a metastasis?, CANCER, 86(12), 1999, pp. 2589-2592
Authors:
Yarbro, JW
Page, DL
Fielding, LP
Partridge, EE
Murphy, GP
Citation: Jw. Yarbro et al., American Joint Committee on Cancer Prognostic Factors Consensus Conference, CANCER, 86(11), 1999, pp. 2436-2446
Authors:
Dupont, WD
Page, DL
Parl, FF
Plummer, WD
Schuyler, PA
Kasami, M
Jensen, RA
Citation: Wd. Dupont et al., Estrogen replacement therapy in women with a history of proliferative breast disease, CANCER, 85(6), 1999, pp. 1277-1283
Authors:
Gobbi, H
Simpson, JF
Borowsky, A
Jensen, RA
Page, DL
Citation: H. Gobbi et al., Metaplastic breast tumors with a dominant fibromatosis-like phenotype havea high risk of local recurrence, CANCER, 85(10), 1999, pp. 2170-2182
Authors:
Goldstein, RE
O'Neill, JA
Holcomb, GW
Morgan, WM
Neblett, WW
Oates, JA
Brown, N
Nadeau, J
Smith, B
Page, DL
Abumrad, NN
Scott, HW
Citation: Re. Goldstein et al., Clinical experience over 48 years with pheochromocytoma, ANN SURG, 229(6), 1999, pp. 755-764
Authors:
Page, DL
Jensen, RA
Simpson, JF
Citation: Dl. Page et al., Routinely available indicators of prognosis in breast cancer, BREAST CANC, 51(3), 1998, pp. 195-208
Authors:
Page, DL
Dupont, WD
Citation: Dl. Page et Wd. Dupont, Benign breast diseases and premalignant breast disease, ARCH PATH L, 122(12), 1998, pp. 1048-1050